AXGN - AxoGen Inc Stock Price, Fair Value and News

9.22USD-0.11 (-1.18%)Market Closed

Market Summary

USD9.22-0.11

Market Closed

-1.18%

AXGN Stock Price

View Fullscreen

AXGN RSI Chart

AXGN Valuation

Market Cap

403.0M

Price/Earnings (Trailing)

-18.94

Price/Sales (Trailing)

2.46

EV/EBITDA

-49.84

Price/Free Cashflow

-19.14

AXGN Price/Sales (Trailing)

AXGN Profitability

EBT Margin

-9.26%

Return on Equity

-22.84%

Return on Assets

-11.41%

Free Cashflow Yield

-5.22%

AXGN Fundamentals

AXGN Revenue

Revenue (TTM)

163.7M

Rev. Growth (Yr)

12.86%

Rev. Growth (Qtr)

-3.6%

AXGN Earnings

Earnings (TTM)

-21.3M

Earnings Growth (Yr)

6.21%

Earnings Growth (Qtr)

-70.43%

Breaking Down AXGN Revenue

Last 7 days

1.1%

Last 30 days

22.9%

Last 90 days

39.1%

Trailing 12 Months

12.7%

How does AXGN drawdown profile look like?

AXGN Financial Health

Current Ratio

3.43

Debt/Equity

0.5

Debt/Cashflow

-0.23

AXGN Investor Care

Shares Dilution (1Y)

2.04%

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	163.7M	0	0	0
2023	144.2M	147.9M	152.3M	159.0M
2022	127.3M	128.2M	134.0M	138.6M
2021	119.1M	130.5M	128.3M	127.4M
2020	107.7M	103.1M	108.0M	112.3M
2019	90.0M	96.1M	102.0M	106.7M
2018	65.4M	70.9M	77.5M	83.9M
2017	45.2M	50.0M	54.9M	60.4M
2016	30.5M	34.5M	37.5M	41.1M
2015	18.6M	20.8M	24.3M	27.3M
2014	11.9M	13.3M	15.0M	16.8M
2013	8.2M	9.0M	10.0M	10.9M
2012	5.4M	6.2M	7.0M	7.7M
2011	3.5M	3.9M	4.4M	4.8M
2010	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About AxoGen Inc

AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

CEO	Ms. Karen Zaderej
WEBSITE	axogeninc.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	394

AxoGen Inc Frequently Asked Questions

What is the ticker symbol for AxoGen Inc? What does AXGN stand for in stocks?

AXGN is the stock ticker symbol of AxoGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AxoGen Inc (AXGN)?

As of Fri Jul 26 2024, market cap of AxoGen Inc is 402.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXGN stock?

You can check AXGN's fair value in chart for subscribers.

Is AxoGen Inc a good stock to buy?

The fair value guage provides a quick view whether AXGN is over valued or under valued. Whether AxoGen Inc is cheap or expensive depends on the assumptions which impact AxoGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXGN.

What is AxoGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, AXGN's PE ratio (Price to Earnings) is -18.94 and Price to Sales (PS) ratio is 2.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AxoGen Inc's stock?

In the past 10 years, AxoGen Inc has provided 0.144 (multiply by 100 for percentage) rate of return.